TTrialPathMatch Me to Trials
← Back to trials
RecruitingDepressionAnxietyMajor Depressive Disorder

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

Eligible age

21–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.

Sponsor: Ohio State University

You may qualify if…

  • ✓ Participant is assigned female or male at birth.
  • ✓ Participant is aged between 21 to 65 years, inclusive, at Screening.
  • ✓ Participant has a BMI of 18 to 30 kg/m2, inclusive, at Screening.
  • ✓ Participant is ≥60 kg.
  • ✓ Participant has a diagnosis of MDD (as defined in the DSM-5 established through a clinician interview that includes the Mini-International Neuropsychiatric Interview)
  • ✓ Depression severity moderate to severe based on MADRS score ≥21.
  • ✓ Anxiety severity moderate to severe based on GAD-7 ≥10.
  • ✓ Inadequate response to current antidepressant medication in current episode of depression.

You may not qualify if…

  • ✕ A reduction in the MADRS score of 25% or more between Screening and Baseline.
  • ✕ Failure to respond to \>2 antidepressant treatments given at an adequate dose for an adequate duration during the current episode of depression.
  • ✕ Current or previously diagnosis of schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or current personality disorder (as determined by MINI at Screening).
  • ✕ Clinically significant risk of suicidality, as determined through a comprehensive psychiatric interview that incorporates the Columbia Suicide Severity Rating Scale (CSSRS); a score of 4 or higher on the suicidal ideation subscale of C-SSRS (past 6 months) or any suicidal behaviour (lifetime), would be exclusionary.
  • ✕ History of substance use disorder within the 12 months, as assessed by a structured clinical interview (Mini International Neuropsychiatric Interview \[MINI\], Version 7.0.2) or determined by self-report, or intake of \>21 units of alcohol weekly, and the inability to refrain from alcohol use from 48 hours before Screening and each scheduled visit until discharge from the study site. One unit is equivalent to a 285 mL glass of full-strength beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine.
  • ✕ Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, other non-SSRI or non-SNRI antidepressants (e.g. bupropion, mirtazapine, etc), an antipsychotic or a mood stabilizer.
  • ✕ Exposure to psilocin, or any other psychedelics, such as ayahuasca, mescaline, LSD or peyote more than 10 times in the last 10 years, or any psychedelic use within 6 months prior to Screening.
  • ✕ Use of psychotropic medicine/supplement (or medicine/supplement that would interact with psilocybin) during the 28 days before dosing. Participants may take a stable chronic dose of antidepressant medication(s) and/or sedatives/hypnotics. The Investigator and study team may review medication on a case-by-case basis to determine if its use would compromise participant safety or interfere with study procedures or data interpretation.

Where it's recruiting

Ohio

Columbus

Source: ClinicalTrials.gov · NCT06820723 · last updated 2026-10-20

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants · TrialPath